Journal
ANNUAL REVIEW OF MEDICINE, VOL 70
Volume 70, Issue -, Pages 323-334Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-042017-094221
Keywords
sodium-glucose cotransporter-2 inhibitors; SGLT-2; type 2 diabetes mellitus; T2DM; glucose lowering; cardiovascular disease
Categories
Ask authors/readers for more resources
Clinical studies evaluating the cardiovascular safety/ impact of sodiumglucose cotransporter-2 (SGLT-2) inhibitors demonstrated a reduction in major adverse cardiovascular events driven primarily by a reduced cardiovascular mortality in individuals with type 2 diabetes and previous cardiovascular disease. These somewhat unexpected results are coupled with SGLT-2 inhibitors' known acute effect of improvement in glycemia, reduction in blood pressure, and weight loss. In this review, we summarize the mechanism of action of SGLT-2 inhibitors, the metabolic effects of this class of medication, and the remarkable results of cardiovascular safety trials. In addition, we discuss adverse effects associated with these medications and the current recommendations for the use of these agents in the management of diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available